ARCTICZYMES TECHNOLOGIES ASA |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 23,65 NOK | +2,83 % |
|
-6,34 % | -43,69 % |
| 13.05. | ArcticZymes Technologies ASA kündigt Rücktritte im Vorstand an | CI |
| 08.05. | ArcticZymes Technologies ASA meldet Ergebnis für das erste Quartal bis zum 31. März 2024 | CI |
Kurzporträt
Umsatz nach Geschäftsbereich
| NOK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Enzymes
100,0
%
| 137 | 100,0 % | 119 | 100,0 % | -13,16 % |
Umsatz je Region
| NOK in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
44,7
%
| 60 | 44,1 % | 53 | 44,7 % | -11,94 % |
Lithuania
29,0
%
| 28 | 20,5 % | 35 | 29,0 % | +23,15 % |
Other Countries in Europe
11,0
%
| 18 | 13,0 % | 13 | 11,0 % | -26,47 % |
Germany
6,0
%
| 12 | 8,8 % | 7 | 6,0 % | -40,48 % |
Rest of World
3,8
%
| 16 | 11,5 % | 5 | 3,8 % | -71,34 % |
France
2,9
%
| - | - | 3 | 2,9 % | - |
Italy
2,4
%
| 3 | 1,9 % | 3 | 2,4 % | +9,83 % |
Norway
0,2
%
| 0 | 0,3 % | 0 | 0,2 % | -48,86 % |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Michael Akoh
CEO | Chief Executive Officer | - | 18.09.23 |
Børge Sørvoll
DFI | Director of Finance/CFO | 49 | 01.10.14 |
Darren Ellis
CTO | Chief Tech/Sci/R&D Officer | - | 01.12.22 |
| Chief Operating Officer | 56 | - | |
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01.01.00 |
Dirk Hahneiser
SAM | Sales & Marketing | 56 | 01.01.22 |
Dino DiCamillo
SAM | Sales & Marketing | 66 | 01.01.12 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Olav Lanes
CTO | Chief Tech/Sci/R&D Officer | 52 | 01.01.00 |
| Chief Operating Officer | 56 | - | |
Bernd Striberny
BRD | Director/Board Member | - | - |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 50 871 390 | 35 904 791 ( 70,58 %) | 0 | 70,58 % |
Unternehmenskontakt
ArcticZymes Technologies ASA
Siva Innovasjonssenter Sykehusveien 23
9019, Tromsø
+47 77 64 89 00
http://www.arcticzymes.com
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. |
Pharmaceuticals: Major
|
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The private company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. |
Medical Specialties
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| -43,69 % | 108 Mio. | |
| +29,77 % | 49,18 Mrd. | |
| +1,00 % | 42,11 Mrd. | |
| +50,47 % | 40,37 Mrd. | |
| -5,26 % | 28,85 Mrd. | |
| +13,68 % | 26,09 Mrd. | |
| -22,99 % | 18,71 Mrd. | |
| +8,22 % | 13,26 Mrd. | |
| +32,41 % | 12,32 Mrd. | |
| -1,62 % | 11,99 Mrd. |
- Börse
- Aktien
- A0HGR5 Aktie
- Unternehmen ArcticZymes Technologies ASA
